TriSalus Life Sciences, Inc. NASDAQ:TLSI

TriSalus Life Sciences stock price today

$4.65
-0.18
-3.93%
Financial Health
0
1
2
3
4
5
6
7
8
9

TriSalus Life Sciences stock price monthly change

-10.37%
month

TriSalus Life Sciences stock price quarterly change

-10.37%
quarter

TriSalus Life Sciences stock price yearly change

-49.16%
year

TriSalus Life Sciences key metrics

Market Cap
124.10M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-6.17
Revenue
21.98M
EBITDA
-55.35M
Income
-63.98M
Revenue Q/Q
116.38%
Revenue Y/Y
68.95%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
-251.79%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

TriSalus Life Sciences stock price history

TriSalus Life Sciences stock forecast

TriSalus Life Sciences financial statements

Average Price Target
Last Year

$10.5

Potential upside: 125.80%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

TriSalus Life Sciences, Inc. (NASDAQ:TLSI): Profit margin
Jun 2023 4.61M -13.97M -302.99%
Sep 2023 5.19M -1.28M -24.76%
Dec 2023 5.72M -35.50M -620.68%
Mar 2024 6.45M -13.21M -204.72%
TriSalus Life Sciences, Inc. (NASDAQ:TLSI): Earnings per share (EPS)
2024-04-01 -0.69 -1.56
2024-05-15 -0.65 -0.54
TriSalus Life Sciences, Inc. (NASDAQ:TLSI): Debt to assets
Jun 2023 16811000 215.17M 1279.96%
Sep 2023 33554000 25.06M 74.71%
Dec 2023 25725000 51.66M 200.83%
Mar 2024 17889000 52.81M 295.22%
TriSalus Life Sciences, Inc. (NASDAQ:TLSI): Cash Flow
Jun 2023 -9.22M -30K 6.40M
Sep 2023 -21.45M -1.31M 40.25M
Dec 2023 -8.84M -700K 43K
Mar 2024 -10.86M -66K 3.12M

TriSalus Life Sciences alternative data

TriSalus Life Sciences, Inc. (NASDAQ:TLSI): Employee count
Dec 2023 106
Jan 2024 106
Feb 2024 106
Mar 2024 106
Apr 2024 106
May 2024 112
Jun 2024 112
Jul 2024 101

TriSalus Life Sciences other data

TriSalus Life Sciences, Inc. (NASDAQ:TLSI): Insider trades (number of shares)
Period Buy Sel
Aug 2024 0 9
Sep 2024 19815 0
Nov 2024 15727 0
Dec 2024 62972 30000
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
FRANKENIUS EQUITY AB 10 percent owner
Common Stock 62,972 $3.97 $249,999
Sale
DESAI ARJUN JJ director
Common Stock 30,000 $3.69 $110,700
Purchase
WAHLSTROM MATS director, 10 percent owner:
Common Stock 5,000 $4.55 $22,750
Purchase
WAHLSTROM MATS director, 10 percent owner:
Common Stock 8,687 $4.44 $38,570
Purchase
WAHLSTROM MATS director, 10 percent owner:
Common Stock 2,040 $4.16 $8,486
Purchase
SZELA MARY T director, officer: CEO AND PRES..
Common Stock 6,000 $5 $30,000
Purchase
SZELA MARY T director, officer: CEO AND PRES..
Common Stock 1,295 $4.83 $6,255
Purchase
SZELA MARY T director, officer: CEO AND PRES..
Common Stock 7,520 $5.2 $39,104
Purchase
SZELA MARY T director, officer: CEO AND PRES..
Common Stock 5,000 $4.97 $24,850
Sale
MARTIN GEORGE KELLY director
Common Stock 9 $5.5 $50
Tuesday, 24 December 2024
seekingalpha.com
Thursday, 14 November 2024
seekingalpha.com
Monday, 11 November 2024
businesswire.com
https://thefly.com
Thursday, 31 October 2024
businesswire.com
Monday, 14 October 2024
businesswire.com
Thursday, 15 August 2024
seekingalpha.com
Wednesday, 26 June 2024
businesswire.com
Tuesday, 25 June 2024
seekingalpha.com
Monday, 3 June 2024
businesswire.com
Friday, 24 May 2024
businesswire.com
Wednesday, 15 May 2024
Seeking Alpha
Monday, 6 May 2024
Business Wire
  • What's the price of TriSalus Life Sciences stock today?

    One share of TriSalus Life Sciences stock can currently be purchased for approximately $4.65.

  • When is TriSalus Life Sciences's next earnings date?

    Unfortunately, TriSalus Life Sciences's (TLSI) next earnings date is currently unknown.

  • Does TriSalus Life Sciences pay dividends?

    No, TriSalus Life Sciences does not pay dividends.

  • How much money does TriSalus Life Sciences make?

    TriSalus Life Sciences has a market capitalization of 124.10M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 49.31% to 18.51M US dollars. TriSalus Life Sciences made a loss 59.04M US dollars in net income (profit) last year or -$0.54 on an earnings per share basis.

  • What is TriSalus Life Sciences's stock symbol?

    TriSalus Life Sciences, Inc. is traded on the NASDAQ under the ticker symbol "TLSI".

  • What is TriSalus Life Sciences's primary industry?

    Company operates in the Healthcare sector and Medical - Devices industry.

  • How do i buy shares of TriSalus Life Sciences?

    Shares of TriSalus Life Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does TriSalus Life Sciences have?

    As Jul 2024, TriSalus Life Sciences employs 101 workers, which is 10% less then previous month and 5% less then previous quarter.

  • When TriSalus Life Sciences went public?

    TriSalus Life Sciences, Inc. is publicly traded company for more then 4 years since IPO on 8 Feb 2021.

  • What is TriSalus Life Sciences's official website?

    The official website for TriSalus Life Sciences is trisaluslifesci.com.

  • Where are TriSalus Life Sciences's headquarters?

    TriSalus Life Sciences is headquartered at 6272 West 91st Avenue, Westminster, CO.

  • How can i contact TriSalus Life Sciences?

    TriSalus Life Sciences's mailing address is 6272 West 91st Avenue, Westminster, CO and company can be reached via phone at +888 3215212.

  • What is TriSalus Life Sciences stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for TriSalus Life Sciences in the last 12 months, the avarage price target is $10.5. The average price target represents a 125.80% change from the last price of $4.65.

TriSalus Life Sciences company profile:

TriSalus Life Sciences, Inc.

trisaluslifesci.com
Exchange:

NASDAQ

Full time employees:

107

Industry:

Medical - Devices

Sector:

Healthcare

TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.

6272 West 91st Avenue
Westminster, CO 80031

CIK: 0001826667
ISIN: US89680M1018
CUSIP: 89680M101